BBIO · NASDAQ · Biotechnology

BridgeBio Pharma

Develops and commercializes genetically targeted medicines through a decentralized portfolio model.

$76.60
After-hours close+0.02 (+0.03%)
At close$76.58(−2.67%)

Breakdown13F · Form 4

Institutions 106.06%Insiders 1.63%

A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.

Shares outstanding 195.86M · Float 169.19M · 86.4% free float

A Form 4 total here can count shares the filer formally disclaims — an award voted by proxy, for instance — which the holder's own Schedule 13D/G excludes, so where the two disagree the schedule's smaller figure is used.

Top shareholders13F · 13D/G · Form 4

HolderShares% outstandingFormFiled
Jupiter Topco LLC14.11M7.20%13FAug 14, 2026
Kohlberg Kravis Roberts & Co. L.P.13.26M6.77%13FAug 14, 2026
KKR Genetic Disorder L.P. · 10 percent owner13.26M6.77%Form 4May 14, 2025
Janus Henderson Group PLC13.18M6.80%13GMay 15, 2026
Farallon Capital Management LLC10.74M5.49%13FAug 14, 2026

Institutions13F, as of Jun 30, 2026

511 holders · 207.73M shares · 89 new positions · 254 increased · 177 reduced · 73 closed

HolderShares% outstandingChg q/qFiled
Jupiter Topco LLC14.11M7.20%+14.11MnewAug 14, 2026
Kohlberg Kravis Roberts & Co. L.P.13.26M6.77%0Aug 14, 2026
Farallon Capital Management LLC10.74M5.49%+1.38MAug 14, 2026
BlackRock, Inc.10.29M5.25%−3.92MAug 7, 2026
Viking Global Investors LP9.95M5.08%−1.89MAug 14, 2026
Vanguard Capital Management LLC7.90M4.03%+139.5KAug 13, 2026
Vanguard Portfolio Management LLC7.66M3.91%−423.9KAug 13, 2026
Wellington Management Group LLP5.31M2.71%+2.82MAug 14, 2026

Beneficial owners13D/G · 5% or more, as filed

Holder% of classSharesFormFiled
Janus Henderson Group PLC6.80%13.18M13GMay 15, 2026
BlackRock, Inc.6.80%12.88MOct 22, 2024
Viking Global Investors LPincl. Shabet Rose Sharon, Halvorsen Ole Andreas +4 more5.00%9.79M13DJul 10, 2026

InsidersForm 4

InsiderRoleShares% outstandingFiled
KKR Genetic Disorder L.P.10 percent owner13.26M6.77%May 14, 2025
Viking Global Investors LP10 percent owner9.79M5.00%Jul 1, 2025
Charles J. Homcydirector919.9K0.47%Jun 24, 2026
Neil Kumardirector, officer: Chief Executive Officer749.0K0.38%Aug 20, 2026
Frank Mccormickdirector690.6K0.35%Jun 24, 2026
Thomas Trimarchiofficer: President and CFO336.5K0.17%Aug 18, 2026
Ali J. Satvatdirector170.0K0.09%Jun 24, 2026
Maricel Apuliofficer: Chief Accounting Officer122.7K0.06%Aug 18, 2026
Andrew Lodirector68.7K0.04%Jun 24, 2026
Fred Hassandirector29.9K0.02%Jun 24, 2026

4 ten-percent owners hold 71.69M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 8 people have not refiled in the last 18 months (506.3K shares), so they are not in the figure above

Latest trades

DateInsiderTypeSharesAvg priceOwned after
Aug 19, 2026
Neil Kumardirector, officer: Chief Executive Officer
Sale · 3 lots10,000$84.03505,686
Aug 18, 2026
Neil Kumardirector, officer: Chief Executive Officer
Sale · 4 lots34,980$82.53243,327
Jul 30, 2026
Maricel Apuliofficer: Chief Accounting Officer
Sale2,000$80.06127,401
Jul 9, 2026
Jennifer E. Cookdirector
Sale · 2 lots148,589$88.548,383
Jul 9, 2026
Andrea Ellisdirector
Sale17,167$84.0022,579
Jun 23, 2026
Hannah Valantinedirector
Sale2,196$68.579,259
Jun 22, 2026
Hannah Valantinedirector
Sale2,808$68.0011,455
Jun 23, 2026
Jennifer E. Cookdirector
Sale2,196$68.578,383
Jun 24, 2026
Jennifer E. Cookdirector
Sale37,167$70.008,383
Jun 15, 2026
Jennifer E. Cookdirector
Sale · 2 lots90,240$66.626,589

CongressHouse and Senate disclosures

MemberTypeAmountOwnerTradedDisclosed
Rep. Gilbert Cisneros · CA31Purchase$1,001 – $15,000May 11, 2026Jun 9, 2026
Rep. Gilbert Cisneros · CA31Purchase$1,001 – $15,000Apr 29, 2026May 11, 2026
Rep. Gilbert Cisneros · CA31Purchase$1,001 – $15,000Mar 19, 2026Apr 8, 2026
Rep. Gilbert Cisneros · CA31Purchase$1,001 – $15,000Mar 18, 2026Apr 8, 2026
Rep. Gilbert Cisneros · CA31Purchase$1,001 – $15,000Mar 3, 2026Apr 8, 2026